Mirum Pharmaceuticals Names Liver Disease Specialist as Chief Medical Officer
Event summary
- Mirum Pharmaceuticals appointed Dr. Rob Myers as Chief Medical Officer, effective September 21, 2026.
- Dr. Myers brings over 20 years of experience in liver disease and rare disease drug development.
- He previously served as Chief Medical Officer at OrsoBio and held senior roles at Gilead Sciences.
- Mirum also announced the departure of Joanne Quan, M.D., from the company.
The big picture
Mirum Pharmaceuticals' appointment of Dr. Rob Myers as Chief Medical Officer underscores its strategic focus on rare liver diseases and its expanding pipeline. The move comes at a critical juncture as the company aims to grow its commercial portfolio and advance multiple late-stage clinical programs. Dr. Myers' extensive experience in hepatology and drug development aligns with Mirum's goal of addressing conditions with historically limited treatment options.
What we're watching
- Pipeline Progression
- How Dr. Myers' expertise will accelerate Mirum's late-stage pipeline, particularly in primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).
- Commercial Growth
- Whether Mirum can sustain its commercial portfolio growth with the addition of a seasoned liver disease specialist.
- Regulatory Dynamics
- The pace at which Mirum advances its regulatory review for zilurgisertib in fibrodysplasia ossificans progressiva (FOP) under Dr. Myers' leadership.
Related topics